Biolase Inc.
| NASDAQ: BIOL | Healthcare / Medical Devices & Instruments / USA |
| 0.7530 | -0.0313 | -3.99% | Vol 3.21M | 1Y Perf 48.69% |
| Jun 15th, 2021 16:00 DELAYED |
| BID | 0.7501 | ASK | 0.7575 | ||
| Open | 0.7869 | Previous Close | 0.7843 | ||
| Pre-Market | - | After-Market | 0.74 | ||
| - - | -0.01 -1.33% |
| Target Price | 2.00 | Analyst Rating | Strong Buy 1.50 | |
| Potential % | 165.60 | Finscreener Ranking | ★★+ 48.03 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★+ 43.29 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★+ 39.78 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Market Cap | 113.25M | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 40.16 | Earnings Date | 13th May 2021 |
Today's Price Range 0.73250.7870 | 52W Range 0.24501.51 | 5 Year PE Ratio Range -2.10-1.20 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 4.21% | ||
| 1 Month | 7.71% | ||
| 3 Months | -20.29% | ||
| 6 Months | 167.50% | ||
| 1 Year | 48.69% | ||
| 3 Years | -39.76% | ||
| 5 Years | -87.34% | ||
| 10 Years | -97.31% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -136.42 | |||
ROE last 12 Months | -251.70 | |||
ROA (5Y Avg) | -50.62 | |||
ROA last 12 Months | -79.56 | |||
ROC (5Y Avg) | -78.84 | |||
ROC last 12 Months | -87.06 | |||
Return on invested Capital Q | -17.73 | |||
Return on invested Capital Y | -107.74 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 4.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.10 | ||||
| 3.75 | ||||
| 4.52 | ||||
| - | ||||
| -8.20 | ||||
| -0.17 | ||||
| 4.11 | ||||
| 0.22 | ||||
| 103.14M | ||||
| Forward PE | -10.44 | |||
| PEG | -0.14 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.90 | ||||
| 5.10 | ||||
| 0.35 | ||||
| 0.55 | ||||
| -6.50 | ||||
| Leverage Ratio | 3.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 29.00 | ||||
| -58.10 | ||||
| -56.50 | ||||
| -46.30 | ||||
| -68.14 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 26.11M | ||||
| 0.17 | ||||
| -19.55 | ||||
| -13.14 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2021 | -0.05 | -0.06 | -20.00 |
| Q04 2020 | -0.04 | -0.07 | -75.00 |
| Q03 2020 | -0.06 | -0.21 | -250.00 |
| Q02 2020 | -0.19 | -0.12 | 36.84 |
| Q01 2020 | -0.18 | -0.19 | -5.56 |
| Q04 2019 | -0.06 | -0.13 | -116.67 |
| Q03 2019 | -0.25 | -0.25 | 0.00 |
| Q02 2019 | -0.20 | -0.15 | 25.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2019 QR | -0.21 | 0.00 | - |
| 6/2021 QR | -0.04 | 69.23 | Positive |
| 12/2021 FY | -0.14 | - | - |
| 12/2022 FY | -0.08 | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.05 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | 15.00 |
| Volume Overview | |
|---|---|
| Volume | 3.21M |
| Shares Outstanding | 150.40M |
| Trades Count | 5.89K |
| Dollar Volume | 11.29M |
| Avg. Volume | 19.37M |
| Avg. Weekly Volume | 5.76M |
| Avg. Monthly Volume | 3.70M |
| Avg. Quarterly Volume | 5.51M |
Biolase Inc. (NASDAQ: BIOL) stock closed at 0.753 per share at the end of the most recent trading day (a -3.99% change compared to the prior day closing price) with a volume of 3.24M shares and market capitalization of 113.25M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 157 people. Biolase Inc. CEO is John R. Beaver.
The one-year performance of Biolase Inc. stock is 48.69%, while year-to-date (YTD) performance is 80.71%. BIOL stock has a five-year performance of -87.34%. Its 52-week range is between 0.245 and 1.51, which gives BIOL stock a 52-week price range ratio of 40.16%
Biolase Inc. currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 3.75, a price-to-sale (PS) ratio of 4.52, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -79.56%, a ROC of -87.06% and a ROE of -251.70%. The company’s profit margin is -68.14%, its EBITDA margin is -56.50%, and its revenue ttm is $26.11 Million , which makes it $0.17 revenue per share.
Of the last four earnings reports from Biolase Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Biolase Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Biolase Inc. is Strong Buy (1.5), with a target price of $2, which is +165.60% compared to the current price. The earnings rating for Biolase Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biolase Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biolase Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 35.01, ATR14 : 0.06, CCI20 : 79.45, Chaikin Money Flow : 0.00, MACD : 0.01, Money Flow Index : 72.46, ROC : 7.01, RSI : 51.47, STOCH (14,3) : 48.79, STOCH RSI : 0.23, UO : 48.92, Williams %R : -51.21), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biolase Inc. in the last 12-months were: John R. Beaver (Buy at a value of $30 000)
Biolase Inc.
Biolase Inc is a US-based medical device company. It develops, manufactures, markets and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products i.e. Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
CEO: John R. Beaver
Telephone: +1 949 361-1200
Address: 4 Cromwell, Irvine 92618, CA, US
Number of employees: 157
